Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Role of the microenvironment in multiple myeloma bone disease.

Huston A, Roodman GD.

Future Oncol. 2006 Jun;2(3):371-8. Review.

PMID:
16787117
2.

Bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A.

Med Oncol. 2006;23(4):431-41. Review.

PMID:
17303901
3.

Myeloma bone disease.

Sezer O.

Hematology. 2005;10 Suppl 1:19-24. Review.

PMID:
16188625
4.

[Bone disease in multiple myeloma and its mechanism].

Abe M.

Clin Calcium. 2006 Apr;16(4):565- 71. Review. Japanese.

PMID:
16582506
5.

Treatment strategies for bone disease.

Roodman GD.

Bone Marrow Transplant. 2007 Dec;40(12):1139-46. Epub 2007 Aug 6. Review.

PMID:
17680018
6.

Myeloma bone disease: pathogenesis, current treatments and future targets.

Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD.

Br Med Bull. 2014 Sep;111(1):117-38. doi: 10.1093/bmb/ldu016. Review.

PMID:
25190762
7.

Therapeutic approaches to myeloma bone disease: an evolving story.

Longo V, Brunetti O, D'Oronzo S, Dammacco F, Silvestris F.

Cancer Treat Rev. 2012 Oct;38(6):787-97. doi: 10.1016/j.ctrv.2012.03.004. Epub 2012 Apr 9. Review.

PMID:
22494965
8.

[Research on mechanism underlying bone damage in myeloma--review].

Zhou LL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Dec;15(6):1340-4. Review. Chinese.

PMID:
18088497
9.

New potential targets for treating myeloma bone disease.

Roodman GD.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6270s-6273s. Review.

10.
11.

Bone markers in multiple myeloma.

Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O.

Eur J Cancer. 2006 Jul;42(11):1544-53. Epub 2006 Jun 9. Review.

PMID:
16765040
12.

Pathogenesis and management of myeloma bone disease.

Christoulas D, Terpos E, Dimopoulos MA.

Expert Rev Hematol. 2009 Aug;2(4):385-98. doi: 10.1586/ehm.09.36. Review.

PMID:
21082944
13.

Myeloma bone disease and proteasome inhibition therapies.

Terpos E, Sezer O, Croucher P, Dimopoulos MA.

Blood. 2007 Aug 15;110(4):1098-104. Epub 2007 May 9. Review.

14.

Dickkopf-1: a suitable target for the management of myeloma bone disease.

Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E.

Expert Opin Ther Targets. 2009 Jul;13(7):839-48. doi: 10.1517/14728220903025770. Review.

PMID:
19530987
15.

Tumor-host cell interactions in the bone disease of myeloma.

Fowler JA, Edwards CM, Croucher PI.

Bone. 2011 Jan;48(1):121-8. doi: 10.1016/j.bone.2010.06.029. Epub 2010 Jul 13. Review.

16.

Myeloma bone disease and treatment options.

Yeh HS, Berenson JR.

Eur J Cancer. 2006 Jul;42(11):1554-63. Epub 2006 Jun 22. Review.

PMID:
16797971
17.

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.

Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O.

Biochem Biophys Res Commun. 2005 Dec 16;338(2):687-93. Epub 2005 Oct 3. Review.

PMID:
16216218
18.

Multiple myeloma/hypercalcemia.

Oyajobi BO.

Arthritis Res Ther. 2007;9 Suppl 1:S4. Review.

20.

Bone turnover following autologous transplantation in multiple myeloma.

Clark RE, Fraser WD.

Leuk Lymphoma. 2002 Mar;43(3):511-6. Review.

PMID:
12002753
Items per page

Supplemental Content

Write to the Help Desk